Goldfinch Bio Announces Licensing Agreement with Takeda for CB1 Monoclonal Antibody for the Treatment of Rare and Metabolic Kidney Diseases
Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced it entered into a license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for worldwide rights to a preclinical, peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody. Goldfinch Bio will assume all development and commercialization responsibilities for the treatment of rare and metabolic kidney diseases worldwide. However, the agreement grants Takeda the option, prior to the initiation of pivotal studies, to request Goldfinch Bio negotiate with Takeda for sub-licensing of Japanese rights to Takeda. Financial terms of the agreement were not disclosed. Goldfinch Bio plans to file an investigational new drug (IND) application for this CB1 inhibitor, re-named GFB-024, in the second half of 2020.
“In recent years, our understanding of the role of CB1 signaling in exacerbating progressive kidney diseases has grown substantially